ArticleOncology letters2020

Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.

Nijia Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.